Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1979 2
1981 2
1991 1
2001 1
2002 2
2003 4
2004 2
2005 1
2006 3
2007 2
2008 4
2009 2
2010 1
2011 1
2012 1
2014 5
2015 1
2016 3
2017 3
2018 5
2019 5
2020 7
2021 3
2022 3
2023 2
2024 1
2025 4
2026 1

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

63 results

Results by year

Filters applied: . Clear all
Your search was processed without automatic term mapping because it retrieved zero results.
Page 1
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction.
McMurray JJV, Solomon SD, Inzucchi SE, Køber L, Kosiborod MN, Martinez FA, Ponikowski P, Sabatine MS, Anand IS, Bělohlávek J, Böhm M, Chiang CE, Chopra VK, de Boer RA, Desai AS, Diez M, Drozdz J, Dukát A, Ge J, Howlett JG, Katova T, Kitakaze M, Ljungman CEA, Merkely B, Nicolau JC, O'Meara E, Petrie MC, Vinh PN, Schou M, Tereshchenko S, Verma S, Held C, DeMets DL, Docherty KF, Jhund PS, Bengtsson O, Sjöstrand M, Langkilde AM; DAPA-HF Trial Committees and Investigators. McMurray JJV, et al. N Engl J Med. 2019 Nov 21;381(21):1995-2008. doi: 10.1056/NEJMoa1911303. Epub 2019 Sep 19. N Engl J Med. 2019. PMID: 31535829 Clinical Trial.
RESULTS: Over a median of 18.2 months, the primary outcome occurred in 386 of 2373 patients (16.3%) in the dapagliflozin group and in 502 of 2371 patients (21.2%) in the placebo group (hazard ratio, 0.74; 95% confidence interval [CI], 0.65 to 0.85; P<0.001). A first wor …
RESULTS: Over a median of 18.2 months, the primary outcome occurred in 386 of 2373 patients (16.3%) in the dapagliflozin group and in 502 of …
Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease.
Ridker PM, Everett BM, Thuren T, MacFadyen JG, Chang WH, Ballantyne C, Fonseca F, Nicolau J, Koenig W, Anker SD, Kastelein JJP, Cornel JH, Pais P, Pella D, Genest J, Cifkova R, Lorenzatti A, Forster T, Kobalava Z, Vida-Simiti L, Flather M, Shimokawa H, Ogawa H, Dellborg M, Rossi PRF, Troquay RPT, Libby P, Glynn RJ; CANTOS Trial Group. Ridker PM, et al. N Engl J Med. 2017 Sep 21;377(12):1119-1131. doi: 10.1056/NEJMoa1707914. Epub 2017 Aug 27. N Engl J Med. 2017. PMID: 28845751 Free article. Clinical Trial.
The hazard ratios as compared with placebo were as follows: in the 50-mg group, 0.93 (95% confidence interval [CI], 0.80 to 1.07; P=0.30); in the 150-mg group, 0.85 (95% CI, 0.74 to 0.98; P=0.021); and in the 300-mg group, 0.86 (95% CI, 0.75 to 0.99; P=0.031) …
The hazard ratios as compared with placebo were as follows: in the 50-mg group, 0.93 (95% confidence interval [CI], 0.80 to 1.07; P=0 …
Microbiota and kidney disease: the road ahead.
Bloom PP, Garrett WS, Penniston KL, Winkler MH, Hazen SL, Agudelo J, Suryavanshi M, Babiker A, Dodd D, Fischbach MA, Huang KC, Huttenhower C, Joe B, Kalantar-Zadeh K, Knight R, Miller AW, Rabb H, Srivastava A, Tang WHW, Turnbaugh PJ, Walker AW, Wilck N, Xu J, Yang T, Himmelfarb J, Redinbo MR, Wu GD, Woodworth MH, Ackerman AL, Winter S, Rinschen MM, Hassan HA, Biruete A, Anderson AH, Pluznick JL. Bloom PP, et al. Nat Rev Nephrol. 2025 Oct;21(10):702-716. doi: 10.1038/s41581-025-00988-5. Epub 2025 Jul 28. Nat Rev Nephrol. 2025. PMID: 40721656 Free PMC article. Review.
Low-Dose Methotrexate for the Prevention of Atherosclerotic Events.
Ridker PM, Everett BM, Pradhan A, MacFadyen JG, Solomon DH, Zaharris E, Mam V, Hasan A, Rosenberg Y, Iturriaga E, Gupta M, Tsigoulis M, Verma S, Clearfield M, Libby P, Goldhaber SZ, Seagle R, Ofori C, Saklayen M, Butman S, Singh N, Le May M, Bertrand O, Johnston J, Paynter NP, Glynn RJ; CIRT Investigators. Ridker PM, et al. N Engl J Med. 2019 Feb 21;380(8):752-762. doi: 10.1056/NEJMoa1809798. Epub 2018 Nov 10. N Engl J Med. 2019. PMID: 30415610 Free PMC article. Clinical Trial.
Triglyceride Lowering with Pemafibrate to Reduce Cardiovascular Risk.
Das Pradhan A, Glynn RJ, Fruchart JC, MacFadyen JG, Zaharris ES, Everett BM, Campbell SE, Oshima R, Amarenco P, Blom DJ, Brinton EA, Eckel RH, Elam MB, Felicio JS, Ginsberg HN, Goudev A, Ishibashi S, Joseph J, Kodama T, Koenig W, Leiter LA, Lorenzatti AJ, Mankovsky B, Marx N, Nordestgaard BG, Páll D, Ray KK, Santos RD, Soran H, Susekov A, Tendera M, Yokote K, Paynter NP, Buring JE, Libby P, Ridker PM; PROMINENT Investigators. Das Pradhan A, et al. N Engl J Med. 2022 Nov 24;387(21):1923-1934. doi: 10.1056/NEJMoa2210645. Epub 2022 Nov 5. N Engl J Med. 2022. PMID: 36342113 Clinical Trial.
Polypill with or without Aspirin in Persons without Cardiovascular Disease.
Yusuf S, Joseph P, Dans A, Gao P, Teo K, Xavier D, López-Jaramillo P, Yusoff K, Santoso A, Gamra H, Talukder S, Christou C, Girish P, Yeates K, Xavier F, Dagenais G, Rocha C, McCready T, Tyrwhitt J, Bosch J, Pais P; International Polycap Study 3 Investigators. Yusuf S, et al. N Engl J Med. 2021 Jan 21;384(3):216-228. doi: 10.1056/NEJMoa2028220. Epub 2020 Nov 13. N Engl J Med. 2021. PMID: 33186492 Free PMC article. Clinical Trial.
Cardiovascular Efficacy and Safety of Bococizumab in High-Risk Patients.
Ridker PM, Revkin J, Amarenco P, Brunell R, Curto M, Civeira F, Flather M, Glynn RJ, Gregoire J, Jukema JW, Karpov Y, Kastelein JJP, Koenig W, Lorenzatti A, Manga P, Masiukiewicz U, Miller M, Mosterd A, Murin J, Nicolau JC, Nissen S, Ponikowski P, Santos RD, Schwartz PF, Soran H, White H, Wright RS, Vrablik M, Yunis C, Shear CL, Tardif JC; SPIRE Cardiovascular Outcome Investigators. Ridker PM, et al. N Engl J Med. 2017 Apr 20;376(16):1527-1539. doi: 10.1056/NEJMoa1701488. Epub 2017 Mar 17. N Engl J Med. 2017. PMID: 28304242 Free article. Clinical Trial.
RESULTS: At 14 weeks, patients in the combined trials had a mean change from baseline in LDL cholesterol levels of -56.0% in the bococizumab group and +2.9% in the placebo group, for a between-group difference of -59.0 percentage points (P<0.001) and a median reduction …
RESULTS: At 14 weeks, patients in the combined trials had a mean change from baseline in LDL cholesterol levels of -56.0% in the bococizumab …
Lipoprotein(a) and Vascular Redox State in Patients With Advanced Coronary Atherosclerosis.
Polkinghorne MD, Badi I, Baragetti A, Chauhan J, Xie C, Wahome E, Akoumianakis I, Foran D, Patel P, de Araujo E, Kotanidis CP, Krasopoulos G, Sayeed R, Srivastava V, Kourliouros A, Walcot N, Sastry P, Guzik T, Channon KM, Norata GD, Antoniades C. Polkinghorne MD, et al. Arterioscler Thromb Vasc Biol. 2026 Jan;46(1):232-247. doi: 10.1161/ATVBAHA.125.322924. Epub 2025 Oct 30. Arterioscler Thromb Vasc Biol. 2026. PMID: 41164877 Free PMC article.
The median follow-up was 5.07 years. RESULTS: Increased plasma Lp(a) (P=0.03) and LPA GRS (P=0.01) were associated with elevated arterial superoxide in the overall patient population, an effect that was driven by nondiabetics. ...Finally, both LPA GRS (hazard ratio, …
The median follow-up was 5.07 years. RESULTS: Increased plasma Lp(a) (P=0.03) and LPA GRS (P=0.01) were associated with elevat …
Identified hadron compositions in p+p and Au+Au collisions at high transverse momenta at S(NN)=200 GeV.
Agakishiev G, Aggarwal MM, Ahammed Z, Alakhverdyants AV, Alekseev I, Alford J, Anderson BD, Anson CD, Arkhipkin D, Averichev GS, Balewski J, Barnby LS, Beavis DR, Bellwied R, Betancourt MJ, Betts RR, Bhasin A, Bhati AK, Bichsel H, Bielcik J, Bielcikova J, Bland LC, Bordyuzhin IG, Borowski W, Bouchet J, Braidot E, Brandin AV, Brovko SG, Bruna E, Bueltmann S, Bunzarov I, Burton TP, Cai XZ, Caines H, Sánchez MC, Cebra D, Cendejas R, Cervantes MC, Chaloupka P, Chattopadhyay S, Chen HF, Chen JH, Chen JY, Chen L, Cheng J, Cherney M, Chikanian A, Christie W, Chung P, Codrington MJ, Corliss R, Cramer JG, Crawford HJ, Cui X, Leyva AD, De Silva LC, Debbe RR, Dedovich TG, Deng J, Derevschikov AA, de Souza RD, Didenko L, Djawotho P, Dong X, Drachenberg JL, Draper JE, Du CM, Dunlop JC, Efimov LG, Elnimr M, Engelage J, Eppley G, Estienne M, Eun L, Evdokimov O, Fachini P, Fatemi R, Fedorisin J, Fersch RG, Filip P, Finch E, Fine V, Fisyak Y, Gagliardi CA, Gangadharan DR, Geurts F, Ghosh P, Gorbunov YN, Gordon A, Grebenyuk OG, Grosnick D, Gupta A, Gupta S, Guryn W, Haag B, Hajkova O, Hamed A, Han LX, Harris JW, Hays-Wehle JP, Heppelmann S, Hirsch A, Hoffmann GW, Hofman DJ, Huang B, Huang HZ, Human… See abstract for full author list ➔ Agakishiev G, et al. Phys Rev Lett. 2012 Feb 17;108(7):072302. doi: 10.1103/PhysRevLett.108.072302. Epub 2012 Feb 14. Phys Rev Lett. 2012. PMID: 22401197
We report transverse momentum (p(T) 15 GeV/c) spectra of pi( ), K( ), p, p[over ], K(S)(0), and rho(0) at midrapidity in p+p and Au+Au collisions at S(NN)=200 GeV. Perturbative QCD calculations are consistent with pi( ) spectra in p+ …
We report transverse momentum (p(T) 15 GeV/c) spectra of pi( ), K( ), p, p[over ], K(S)(0), and rho(0) at midrapidity …
Plasma Levels of Organochlorine Pesticides and Tumor Necrosis Factor-Alpha: A Potential Risk Factor for Developing Acquired Aplastic Anemia in the North Indian Population.
Goel C, Kumar N, Tripathi AK, Tiwari S, Shrivastava A, Shukla S, Mishra A, Srivastava A. Goel C, et al. Cureus. 2023 Sep 28;15(9):e46122. doi: 10.7759/cureus.46122. eCollection 2023 Sep. Cureus. 2023. PMID: 37900403 Free PMC article.
Results There was a significant increase in plasma levels of delta hexachlorocyclohexane (delta HCH) (p = 0.02) and heptachlor (p = 0.00) in patients with AA as compared to controls. We observed nonsignificant trends towards higher levels of beta HCH (p = 0.6 …
Results There was a significant increase in plasma levels of delta hexachlorocyclohexane (delta HCH) (p = 0.02) and heptachlor (p …
63 results